Mirova Purchases 2,482 Shares of Eli Lilly and Company (NYSE:LLY)

Mirova raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 10.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 25,695 shares of the company’s stock after purchasing an additional 2,482 shares during the period. Eli Lilly and Company accounts for approximately 3.4% of Mirova’s holdings, making the stock its 6th biggest position. Mirova’s holdings in Eli Lilly and Company were worth $19,837,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. MML Investors Services LLC increased its position in Eli Lilly and Company by 3.8% in the 4th quarter. MML Investors Services LLC now owns 127,018 shares of the company’s stock valued at $98,058,000 after acquiring an additional 4,657 shares during the period. MetLife Investment Management LLC grew its stake in shares of Eli Lilly and Company by 0.9% in the fourth quarter. MetLife Investment Management LLC now owns 244,080 shares of the company’s stock worth $188,430,000 after purchasing an additional 2,280 shares in the last quarter. NWK Group Inc. increased its holdings in shares of Eli Lilly and Company by 0.9% during the fourth quarter. NWK Group Inc. now owns 15,938 shares of the company’s stock valued at $12,304,000 after purchasing an additional 138 shares during the period. Norinchukin Bank The raised its stake in shares of Eli Lilly and Company by 7.2% during the fourth quarter. Norinchukin Bank The now owns 34,048 shares of the company’s stock valued at $26,285,000 after purchasing an additional 2,280 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S lifted its holdings in Eli Lilly and Company by 27.5% in the fourth quarter. BI Asset Management Fondsmaeglerselskab A S now owns 127,068 shares of the company’s stock worth $98,096,000 after purchasing an additional 27,412 shares during the period. Institutional investors own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. This trade represents a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.14% of the stock is currently owned by insiders.

Eli Lilly and Company Price Performance

LLY opened at $841.70 on Friday. The firm has a market capitalization of $798.08 billion, a P/E ratio of 71.88, a PEG ratio of 1.40 and a beta of 0.51. The stock has a fifty day moving average of $829.09 and a 200-day moving average of $819.86. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Wells Fargo & Company boosted their price target on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Morgan Stanley dropped their target price on Eli Lilly and Company from $1,146.00 to $1,124.00 and set an “overweight” rating on the stock in a report on Wednesday, April 9th. Citigroup decreased their price target on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Berenberg Bank set a $970.00 price objective on Eli Lilly and Company in a research note on Thursday, January 16th. Finally, Truist Financial raised their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research note on Monday, February 3rd. Two equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $1,012.00.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.